194 related articles for article (PubMed ID: 30266470)
1. Resveratrol and Alzheimer's disease. From molecular pathophysiology to clinical trials.
Drygalski K; Fereniec E; Koryciński K; Chomentowski A; Kiełczewska A; Odrzygóźdź C; Modzelewska B
Exp Gerontol; 2018 Nov; 113():36-47. PubMed ID: 30266470
[No Abstract] [Full Text] [Related]
2. Resveratrol--a boon for treating Alzheimer's disease?
Anekonda TS
Brain Res Rev; 2006 Sep; 52(2):316-26. PubMed ID: 16766037
[TBL] [Abstract][Full Text] [Related]
3. In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress.
Perluigi M; Joshi G; Sultana R; Calabrese V; De Marco C; Coccia R; Butterfield DA
Neuroscience; 2006; 138(4):1161-70. PubMed ID: 16427207
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of resveratrol and resveratrol-functional selenium nanoparticles: Inhibiting amyloid β aggregation and reactive oxygen species formation properties.
Yang L; Wang W; Chen J; Wang N; Zheng G
J Biomed Mater Res A; 2018 Dec; 106(12):3034-3041. PubMed ID: 30295993
[TBL] [Abstract][Full Text] [Related]
5. Role of reactive oxygen species in the progression of Alzheimer's disease.
Bhatt S; Puli L; Patil CR
Drug Discov Today; 2021 Mar; 26(3):794-803. PubMed ID: 33306995
[TBL] [Abstract][Full Text] [Related]
6. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal.
Hardy J
J Neurochem; 2009 Aug; 110(4):1129-34. PubMed ID: 19457065
[TBL] [Abstract][Full Text] [Related]
7. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease.
Matsuoka Y; Picciano M; La Francois J; Duff K
Neuroscience; 2001; 104(3):609-13. PubMed ID: 11440793
[TBL] [Abstract][Full Text] [Related]
8. Is intraneuronal amyloid beta-peptide accumulation the trigger of Alzheimer's disease pathophysiology?
Moreira PI; Liu Q; Honda K; Smith MA; Santos MS; Oliveira CR
J Alzheimers Dis; 2004 Aug; 6(4):433-4; discussion 443-9. PubMed ID: 15495345
[No Abstract] [Full Text] [Related]
9. Resveratrol-maltol hybrids as multi-target-directed agents for Alzheimer's disease.
Cheng G; Xu P; Zhang M; Chen J; Sheng R; Ma Y
Bioorg Med Chem; 2018 Dec; 26(22):5759-5765. PubMed ID: 30360953
[TBL] [Abstract][Full Text] [Related]
10. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease--a target for neuroprotective treatment strategies?
Münch G; Deuther-Conrad W; Gasic-Milenkovic J
J Neural Transm Suppl; 2002; (62):303-7. PubMed ID: 12456073
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol for Alzheimer's disease.
Sawda C; Moussa C; Turner RS
Ann N Y Acad Sci; 2017 Sep; 1403(1):142-149. PubMed ID: 28815614
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism.
Deuther-Conrad W; Loske C; Schinzel R; Dringen R; Riederer P; Münch G
Neurosci Lett; 2001 Oct; 312(1):29-32. PubMed ID: 11578838
[TBL] [Abstract][Full Text] [Related]
13. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman.
Selkoe DJ
Neurochem Res; 2003 Nov; 28(11):1705-13. PubMed ID: 14584824
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective Properties of Resveratrol and Its Derivatives-Influence on Potential Mechanisms Leading to the Development of Alzheimer's Disease.
Wiciński M; Domanowska A; Wódkiewicz E; Malinowski B
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326620
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of resveratrol derivatives as Aß(₁-₄₂) aggregation inhibitors, antioxidants, and neuroprotective agents.
Lu C; Guo Y; Li J; Yao M; Liao Q; Xie Z; Li X
Bioorg Med Chem Lett; 2012 Dec; 22(24):7683-7. PubMed ID: 23127891
[TBL] [Abstract][Full Text] [Related]
16. The redox chemistry of the Alzheimer's disease amyloid beta peptide.
Smith DG; Cappai R; Barnham KJ
Biochim Biophys Acta; 2007 Aug; 1768(8):1976-90. PubMed ID: 17433250
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation endproducts in ageing and Alzheimer's disease.
Münch G; Thome J; Foley P; Schinzel R; Riederer P
Brain Res Brain Res Rev; 1997 Feb; 23(1-2):134-43. PubMed ID: 9063589
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer's disease.
Li SY; Wang XB; Kong LY
Eur J Med Chem; 2014 Jan; 71():36-45. PubMed ID: 24269515
[TBL] [Abstract][Full Text] [Related]
19. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.
Cribbs DH; Agadjanyan MG
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):82-7. PubMed ID: 19355929
[No Abstract] [Full Text] [Related]
20. Alzheimer's disease drug discovery: Abeta and beyond.
Shineman DW; Fillit HM
Curr Alzheimer Res; 2010 May; 7(3):188-9. PubMed ID: 20406195
[No Abstract] [Full Text] [Related]
[Next] [New Search]
